Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)

Trial Profile

A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 14 Aug 2019 to 16 Dec 2019.
    • 08 Jan 2019 Planned primary completion date changed from 5 Aug 2019 to 7 Dec 2019.
    • 15 Oct 2018 Planned End Date changed from 9 Jun 2019 to 14 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top